Katherine R. Schultz

<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist et al. · Clinical Cancer Research · 2016 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +10

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non–Small-Cell Lung Cancer

Justin F. Gainor, Diane Tseng, Satoshi Yoda et al. · JCO Precision Oncology · 2017 · 261 citations

Medicine, Oncology, Pharmacology +17

Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda et al. · European Journal of Cancer · 2016 · 195 citations

Medicine, Cancer Biology, Oncology +16

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Justin F. Gainor, Daniel Shao-Weng Tan, Tomasso De Pas et al. · Clinical Cancer Research · 2015 · 178 citations · Full text

Medicine, Oncology, Pharmacology +17